Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

David L. Wyles

TitleAffiliate - DHHA
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/602-5148

    Collapse Research 
    Collapse research activities and funding
    U51PS003924     (WYLES, DAVID L)Sep 30, 2012 - Dec 31, 2014
    NIH
    The Hepatitis Care Connection Program (Hep-Care Connect)
    Role: Principal Investigator
    R21AI097061     (WYLES, DAVID L)Feb 15, 2012 - Jan 31, 2016
    NIH
    Analysis of HIV/HCV Sexual Transmission Pairs Using Ultra-Deep Sequencing
    Role: Principal Investigator
    K08AI069989     (WYLES, DAVID L)Jun 15, 2007 - May 31, 2013
    NIH
    An in vitro system to study antiviral strategies against Hepatitis C virus
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rowan SE, Wyles DL. Don't Put Off Until Tomorrow What You Can Do Today: Hospital Admissions as an Opportunity to Treat Hepatitis C. Clin Infect Dis. 2024 03 20; 78(3):591-593. PMID: 37991385.
      View in: PubMed
    2. Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS). Open Forum Infect Dis. 2023 Mar; 10(3):ofad115. PMID: 37008564.
      View in: PubMed
    3. Anesi GL, Andrews A, Bai HJ, Bhatraju PK, Brett-Major DM, Broadhurst MJ, Campbell ES, Cobb JP, Gonzalez M, Homami S, Hypes CD, Irwin A, Kratochvil CJ, Krolikowski K, Kumar VK, Landsittel DP, Lee RA, Liebler JM, Lutrick K, Marts LT, Mosier JM, Mukherjee V, Postelnicu R, Rodina V, Segal LN, Sevransky JE, Spainhour C, Srivastava A, Uyeki TM, Wurfel MM, Wyles D, Evans L. Perceived Hospital Stress, Severe Acute Respiratory Syndrome Coronavirus 2 Activity, and Care Process Temporal Variance During the COVID-19 Pandemic. Crit Care Med. 2023 04 01; 51(4):445-459. PMID: 36790189.
      View in: PubMed
    4. Rowan SE, Haukoos J, Kamis KF, Hopkins E, Gravitz S, Lyle C, Al-Tayyib AA, Gardner EM, Galbraith JW, Hsieh YH, Lyons MS, Rothman RE, White DAE, Morgan JR, Linas BP, Sabel AL, Wyles DL. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis C. Trials. 2023 Jan 27; 24(1):63. PMID: 36707909.
      View in: PubMed
    5. Bhatraju PK, Morrell ED, Stanaway IB, Sathe NA, Srivastava A, Postelnicu R, Green R, Andrews A, Gonzalez M, Kratochvil CJ, Kumar VK, Hsiang TY, Gale M, Anesi GL, Wyles D, Broadhurst MJ, Brett-Major D, Mukherjee V, Sevransky JE, Landsittel D, Hung C, Altemeier WA, Gharib SA, Uyeki TM, Cobb JP, Liebler JM, Crosslin DR, Jarvik GP, Segal LN, Evans L, Mikacenic C, Wurfel MM. Angiopoietin-Like4 Is a Novel Marker of COVID-19 Severity. Crit Care Explor. 2023 Jan; 5(1):e0827. PMID: 36600780.
      View in: PubMed
    6. Postelnicu R, Srivastava A, Bhatraju PK, Wurfelc MM, Anesi GL, Gonzalez M, Andrews A, Lutrick K, Kumar VK, Uyeki TM, Cobb PJ, Segal LN, Brett-Major D, Liebler JM, Kratochvil CJ, Mukherjee V, Broadhurst MJ, Lee R, Wyles D, Sevransky JE, Evans L, Landsittel D. Severe Acute Respiratory Infection-Preparedness: Protocol for a Multicenter Prospective Cohort Study of Viral Respiratory Infections. Crit Care Explor. 2022 Oct; 4(10):e0773. PMID: 36284548.
      View in: PubMed
    7. Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman J, Trooskin SB, Lo Re V. The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population. Open Forum Infect Dis. 2022 Sep; 9(9):ofac445. PMID: 36092829.
      View in: PubMed
    8. Kamis KF, Wyles DL, Minturn MS, Scott T, McEwen D, Hurley H, Prendergast SJ, Gunter J, Rowan SE. A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probation. Health Justice. 2022 Aug 10; 10(1):26. PMID: 35947313.
      View in: PubMed
    9. Adje YH, Brooks KM, Castillo-Mancilla JR, Wyles DL, Anderson PL, Kiser JJ. The use of technology-based adherence monitoring in the treatment of hepatitis C virus. Ther Adv Infect Dis. 2022 Jan-Dec; 9:20499361221095664. PMID: 35591885.
      View in: PubMed
    10. Brooks KM, Castillo-Mancilla JR, Morrow M, Mawhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah L, Tehrani A, Jimmerson LC, Roon L, Bushman LR, Anderson PL, Kiser JJ. Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use. J Antimicrob Chemother. 2022 04 27; 77(5):1396-1403. PMID: 35194648.
      View in: PubMed
    11. Haukoos JS, Rowan SE, Galbraith JW, Rothman RE, Hsieh YH, Hopkins E, Houk RA, Toerper MF, Kamis KF, Morgan JR, Linas BP, Al-Tayyib AA, Gardner EM, Lyons MS, Sabel AL, White DAE, Wyles DL. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments. Trials. 2022 Apr 25; 23(1):354. PMID: 35468807.
      View in: PubMed
    12. Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 04; 7(4):307-317. PMID: 35026142.
      View in: PubMed
    13. Aronsohn AI, Bhattacharya D, Morgan TR, Wyles DL, Chung RT, McQuillen DP. Reply. Hepatology. 2022 04; 75(4):1055-1056. PMID: 34859470.
      View in: PubMed
    14. Kamis KF, Wyles DL, Minturn MS, Scott T, McEwen D, Hurley H, Prendergast SJ, Rowan SE. Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City. Open Forum Infect Dis. 2022 Feb; 9(2):ofab636. PMID: 35111867.
      View in: PubMed
    15. Sulkowski M, Wyles D. D?j? vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions. Clin Infect Dis. 2021 11 02; 73(9):e3296-e3299. PMID: 32887999.
      View in: PubMed
    16. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, Wolfe CR, Ruiz-Palacios GM, Kline S, Regalado Pineda J, Luetkemeyer AF, Harkins MS, Jackson PEH, Iovine NM, Tapson VF, Oh MD, Whitaker JA, Mularski RA, Paules CI, Ince D, Takasaki J, Sweeney DA, Sandkovsky U, Wyles DL, Hohmann E, Grimes KA, Grossberg R, Laguio-Vila M, Lambert AA, Lopez de Castilla D, Kim E, Larson L, Wan CR, Traenkner JJ, Ponce PO, Patterson JE, Goepfert PA, Sofarelli TA, Mocherla S, Ko ER, Ponce de Leon A, Doernberg SB, Atmar RL, Maves RC, Dangond F, Ferreira J, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd L, Tomashek KM, Beigel JH. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376. PMID: 34672949.
      View in: PubMed
    17. Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2021 Dec; 8(12):ofab511. PMID: 34926713.
      View in: PubMed
    18. Luetkemeyer AF, Wyles DL. CROI 2021: Viral Hepatitis and Other Forms of Liver Injury Impacting People with HIV. Top Antivir Med. 2021 Jun-Jul; 29(3):379-385. PMID: 34370419.
      View in: PubMed
    19. Auma AWN, Shive C, Damjanovska S, Kowal C, Cohen DE, Bhattacharya D, Alston-Smith B, Osborne M, Kalayjian R, Balagopal A, Sulkowski M, Wyles D, Anthony DD. T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. Open Forum Infect Dis. 2021 Apr; 8(4):ofab079. PMID: 33880389.
      View in: PubMed
    20. Naggie S, Wyles D. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. J Infect Dis. 2020 11 27; 222(Suppl 9):S741-S744. PMID: 33245351.
      View in: PubMed
    21. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Rowan SE, Wyles D, Blum J, Huntley R, Salah LM, Tehrani A, Bushman LR, Anderson PL, Kiser JJ. Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infect Dis. 2021 Jan; 8(1):ofaa564. PMID: 33447634.
      View in: PubMed
    22. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 11 01; 75(11):3303-3310. PMID: 32766700.
      View in: PubMed
    23. Anthony DD, Sulkowski MS, Smeaton LM, Damjanovska S, Shive CL, Kowal CM, Cohen DE, Bhattacharya D, Alston-Smith BL, Balagopal A, Wyles DL. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. J Infect Dis. 2020 09 14; 222(8):1334-1344. PMID: 32406487.
      View in: PubMed
    24. Balagopal A, Smeaton LM, Quinn J, Venuto CS, Morse GD, Vu V, Alston-Smith B, Cohen DE, Santana-Bagur JL, Anthony DD, Sulkowski MS, Wyles DL, Talal AH. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. J Infect Dis. 2020 07 23; 222(4):601-610. PMID: 32201883.
      View in: PubMed
    25. Vazquez Deida AA, Shihadeh KC, Preslaski CR, Young HL, Wyles DL, Jenkins TC. Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy. Open Forum Infect Dis. 2020 Aug; 7(8):ofaa293. PMID: 32793767.
      View in: PubMed
    26. Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Aliment Pharmacol Ther. 2020 06; 51(12):1384-1396. PMID: 32352586.
      View in: PubMed
    27. Fierer DS, Wyles DL. Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy. Open Forum Infect Dis. 2020 Apr; 7(4):ofaa095. PMID: 32296728.
      View in: PubMed
    28. Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol. 2020 01; 86(1):132-142. PMID: 31656054.
      View in: PubMed
    29. Canfield GS, Henao-Mart?nez AF, Franco-Paredes C, Zhelnin K, Wilson ML, Shihadeh KC, Wyles D, Gardner EM. Corticosteroids for Posttransplant Immune Reconstitution Syndrome in Cryptococcus gattii Meningoencephalitis: Case Report and Literature Review. Open Forum Infect Dis. 2019 Nov; 6(11):ofz460. PMID: 31737740.
      View in: PubMed
    30. Wyles DL. Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease. Clin Liver Dis. 2019 08; 23(3):473-486. PMID: 31266621.
      View in: PubMed
    31. Chaillon A, Sun X, Cachay ER, Looney D, Wyles D, Garfein RS, Martin TCS, Jain S, Mehta SR, Smith DM, Little SJ, Martin NK. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019 Apr; 6(4):ofz160. PMID: 31041355.
      View in: PubMed
    32. Luetkemeyer AF, Wyles DL. CROI 2019: highlights of viral hepatitis. Top Antivir Med. 2019 Apr; 27(1):41-49. PMID: 31137002.
      View in: PubMed
    33. Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019 Aug; 54(8):752-761. PMID: 30868245.
      View in: PubMed
    34. Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 05; 70(5):1019-1023. PMID: 30857780.
      View in: PubMed
    35. Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. J Viral Hepat. 2019 03; 26(3):337-349. PMID: 30421537.
      View in: PubMed
    36. Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infect Dis. 2018 Nov; 5(11):ofy248. PMID: 30430131.
      View in: PubMed
    37. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018 09 14; 67(7):1010-1017. PMID: 29566246.
      View in: PubMed
    38. Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018 Jun; 5(6):ofy103. PMID: 29977962.
      View in: PubMed
    39. Luetkemeyer AF, Wyles DL. CROI 2018: Highlights of Viral Hepatitis. Top Antivir Med. 2018 May; 26(1):30-38. PMID: 29727295.
      View in: PubMed
    40. Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourli?re M, Foster G, Afdhal N, Dore GJ. Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis. 2018 Feb; 5(2):ofy001. PMID: 29450210.
      View in: PubMed
    41. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018 02; 67(2):514-523. PMID: 28926120.
      View in: PubMed
    42. Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H. Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2018; 23(3):229-238. PMID: 28650844.
      View in: PubMed
    43. Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017 12; 14(6):229-237. PMID: 29116550.
      View in: PubMed
    44. Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017 12; 66(6):1794-1804. PMID: 28688129.
      View in: PubMed
    45. Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ? Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis. 2017; 4(3):ofx154. PMID: 28948180.
      View in: PubMed
    46. Wyles D, Br?u N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017 Jul 01; 65(1):6-12. PMID: 28369210.
      View in: PubMed
    47. Wyles DL, Luetkemeyer AF. Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. Top Antivir Med. 2017 Jul/Aug; 25(3):103-109. PMID: 28820725.
      View in: PubMed
    48. Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017 12; 37(12):1796-1804. PMID: 28470938.
      View in: PubMed
    49. Luetkemeyer AF, Wyles DL. CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis. Top Antivir Med. 2017 May/Jun; 25(2):84-92. PMID: 28598793.
      View in: PubMed
    50. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017 08; 67(2):263-271. PMID: 28412293.
      View in: PubMed
    51. Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. J Infect Dis. 2017 02 15; 215(4):599-605. PMID: 28329334.
      View in: PubMed
    52. Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD, Mo H, Gane EJ. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017 04; 66(4):703-710. PMID: 27923693.
      View in: PubMed
    53. Hill LA, Wyles DL. Emerging complexities with hepatitis C virus direct-acting antiviral regimens: Less is still Way more. Hepatology. 2016 11; 64(5):1401-1403. PMID: 27635632.
      View in: PubMed
    54. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, Natha M, Zhu Y, Yang J, Kreter B, Brainard DM, Yun C, Carr V, Dore GJ. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Clin Infect Dis. 2016 Dec 01; 63(11):1405-1411. PMID: 27553375.
      View in: PubMed
    55. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016 10; 151(4):651-659.e1. PMID: 27456384.
      View in: PubMed
    56. Wyles D, Sulkowski MS, Dieterich D. About This Continuing Medical Education Activity. Clin Infect Dis. 2016 07 15; 63 Suppl 1:S1-2. PMID: 27363436.
      View in: PubMed
    57. Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis. 2016 07 15; 63 Suppl 1:S3-S11. PMID: 27363438.
      View in: PubMed
    58. Luetkemeyer AF, Wyles DL. CROI 2016: Viral Hepatitis and Liver Fibrosis. Top Antivir Med. 2016 May-Jun; 24(1):47-58. PMID: 27398862.
      View in: PubMed
    59. Cachay ER, Wyles D, Hill L, Ballard C, Torriani F, Colwell B, Kuo A, Schooley R, Mathews CW. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care. Open Forum Infect Dis. 2015 Dec; 2(4):ofv168. PMID: 26697509.
      View in: PubMed
    60. Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):818-26. PMID: 26551051.
      View in: PubMed
    61. Poveda E, Wyles D, Morano L, Pineda JA, Garc?a F. News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference. AIDS Rev. 2015 Oct-Dec; 17(4):231-7. PMID: 26616846.
      View in: PubMed
    62. Wyles DL. Regimens for Patients Coinfected with Human Immunodeficiency Virus. Clin Liver Dis. 2015 Nov; 19(4):689-706, vi-vii. PMID: 26466656.
      View in: PubMed
    63. Carlin AF, Aristizabal P, Song Q, Wang H, Paulson MS, Stamm LM, Schooley RT, Wyles DL. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology. 2015 Oct; 62(4):1047-58. PMID: 26147061.
      View in: PubMed
    64. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):714-25. PMID: 26196502.
      View in: PubMed
    65. Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015 Jun; 61(6):1793-7. PMID: 25846014.
      View in: PubMed
    66. Kowdley KV, An D, Pang PS, Wyles D. Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection. Open Forum Infect Dis. 2015 Apr; 2(2):ofv056. PMID: 26380348.
      View in: PubMed
    67. Luetkemeyer AF, Wyles DL. CROI 2015: Highlights of Viral Hepatitis Therapy. Top Antivir Med. 2015 Mar-Apr; 23(1):66-76. PMID: 25965313.
      View in: PubMed
    68. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015 Mar 24-31; 313(12):1223-31. PMID: 25706092.
      View in: PubMed
    69. Boerneke MA, Dibrov SM, Gu J, Wyles DL, Hermann T. Functional conservation despite structural divergence in ligand-responsive RNA switches. Proc Natl Acad Sci U S A. 2014 Nov 11; 111(45):15952-7. PMID: 25349403.
      View in: PubMed
    70. Gutierrez JA, Jones KA, Flores R, Singhania A, Woelk CH, Schooley RT, Wyles DL. Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression. J Virol Antivir Res. 2014 Oct 06; 3(3). PMID: 26594646.
      View in: PubMed
    71. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014 Dec 15; 59(12):1666-74. PMID: 25266287.
      View in: PubMed
    72. Pernas B, Grandal M, Mena A, Castro-Iglesias A, Ca?izares A, Wyles DL, L?pez-Calvo S, P?rtega S, Rodr?guez-Osorio I, Pedreira JD, Poveda E. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS. 2014 Jul 31; 28(12):1837-40. PMID: 24871456.
      View in: PubMed
    73. Cachay ER, Hill L, Wyles D, Colwell B, Ballard C, Torriani F, Mathews WC. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One. 2014; 9(7):e102883. PMID: 25036553.
      View in: PubMed
    74. Lin JC, Habersetzer F, Rodriguez-Torres M, Afdhal N, Lawitz EJ, Paulson MS, Zhu Y, Subramanian GM, McHutchison JG, Sulkowski M, Wyles DL, Schooley RT. Interferon ?-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J Infect Dis. 2014 Dec 15; 210(12):1881-5. PMID: 24907384.
      View in: PubMed
    75. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014 Aug; 108:181-91. PMID: 24911972.
      View in: PubMed
    76. Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-na?ve patients with genotype 1 HCV infection. Hepatology. 2014 Jul; 60(1):56-64. PMID: 24501005.
      View in: PubMed
    77. Beckett GA, Ramirez G, Vanderhoff A, Nichols K, Chute SM, Wyles DL, Schoenbachler BT, Bedell DT, Cabral R, Ward JW. Early identification and linkage to care of persons with chronic hepatitis B virus infection--three U.S. sites, 2012-2014. MMWR Morb Mortal Wkly Rep. 2014 May 09; 63(18):399-401. PMID: 24807238.
      View in: PubMed
    78. Cachay ER, Wyles DL, Torriani FJ, Ballard C, Colwell B, Lin JC, Hill L, Mathews WC. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. AIDS. 2013 Nov 28; 27(18):2893-7. PMID: 23842130.
      View in: PubMed
    79. Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis. 2014 Mar 01; 209(5):658-67. PMID: 24041792.
      View in: PubMed
    80. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16; 368(20):1878-87. PMID: 23607594.
      View in: PubMed
    81. Cachay ER, Hill L, Ballard C, Colwell B, Torriani F, Wyles D, Mathews WC. Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Res Ther. 2013 Mar 28; 10(1):9. PMID: 23537147.
      View in: PubMed
    82. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013 Mar; 207 Suppl 1:S33-9. PMID: 23390303.
      View in: PubMed
    83. Wyles DL. Hepatitis C virus drug resistance: implications for clinical management. Infect Dis Clin North Am. 2012 Dec; 26(4):967-78. PMID: 23083827.
      View in: PubMed
    84. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med. 2012 Oct-Nov; 20(4):139-45. PMID: 23154254.
      View in: PubMed
    85. Wegzyn CM, Wyles DL. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Curr Opin Pharmacol. 2012 Oct; 12(5):556-61. PMID: 22770811.
      View in: PubMed
    86. Dibrov SM, Ding K, Brunn ND, Parker MA, Bergdahl BM, Wyles DL, Hermann T. Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches. Proc Natl Acad Sci U S A. 2012 Apr 03; 109(14):5223-8. PMID: 22431596.
      View in: PubMed
    87. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012 Feb 15; 205(4):656-62. PMID: 22279172.
      View in: PubMed
    88. Cachay ER, Wyles DL, Goicoechea M, Torriani FJ, Ballard C, Colwell B, Gish RG, Mathews WC. Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Res Ther. 2011 Aug 10; 8:29. PMID: 21831314.
      View in: PubMed
    89. Valiaeva N, Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem. 2011 Aug 01; 19(15):4616-25. PMID: 21719300.
      View in: PubMed
    90. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis. 2011 Mar 15; 52(6):812-8. PMID: 21282184.
      View in: PubMed
    91. Wyles DL. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med. 2010 Oct-Nov; 18(4):132-6. PMID: 21107012.
      View in: PubMed
    92. Carnevali M, Parsons J, Wyles DL, Hermann T. A modular approach to synthetic RNA binders of the hepatitis C virus internal ribosome entry site. Chembiochem. 2010 Jul 05; 11(10):1364-7. PMID: 20564282.
      View in: PubMed
    93. Wyles DL, Schooley RT. Rong's numbers: accelerating progress in HCV therapeutic research. Sci Transl Med. 2010 May 26; 2(33):33ps25. PMID: 20505213.
      View in: PubMed
    94. Parsons J, Castaldi MP, Dutta S, Dibrov SM, Wyles DL, Hermann T. Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA. Nat Chem Biol. 2009 Nov; 5(11):823-5. PMID: 19767736.
      View in: PubMed
    95. Morrey JD, Korba BE, Beadle JR, Wyles DL, Hostetler KY. Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. Antimicrob Agents Chemother. 2009 Jul; 53(7):2865-70. PMID: 19398648.
      View in: PubMed
    96. Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY. The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother. 2009 Jun; 53(6):2660-2. PMID: 19289518.
      View in: PubMed
    97. Wyles DL. Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: a marker for nonliver, non-opportunistic disease mortality. Clin Infect Dis. 2008 Dec 01; 47(11):1476-8. PMID: 18959495.
      View in: PubMed
    98. Wyles DL, Kaihara KA, Schooley RT. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. Antimicrob Agents Chemother. 2008 May; 52(5):1862-4. PMID: 18332167.
      View in: PubMed
    99. Gr?nberger C, Wyles DL, Kaihara KA, Schooley RT. 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis. 2008 Jan 01; 197(1):42-5. PMID: 18171283.
      View in: PubMed
    100. Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007 Mar; 81(6):3005-8. PMID: 17182685.
      View in: PubMed
    101. Wyles DL, Patel A, Madinger N, Bessesen M, Krause PR, Weinberg A. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clin Infect Dis. 2005 Sep 01; 41(5):676-80. PMID: 16080090.
      View in: PubMed
    102. Wyles DL, Gerber JG. Abacavir pharmacokinetics in hepatic dysfunction. Clin Infect Dis. 2005 Mar 15; 40(6):909-10. PMID: 15736035.
      View in: PubMed
    103. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005 Jan 01; 40(1):174-81. PMID: 15614709.
      View in: PubMed
    Wyles's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (232) concept(s)
    _
    Co-Authors Expand Description
    See all (16) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)